239 related articles for article (PubMed ID: 23473546)
1. Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program.
Szegedi A; Zhao J; McIntyre RS
J Affect Disord; 2013 Sep; 150(3):745-52. PubMed ID: 23473546
[TBL] [Abstract][Full Text] [Related]
2. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.
Chwieduk CM; Scott LJ
CNS Drugs; 2011 Mar; 25(3):251-67. PubMed ID: 21323396
[TBL] [Abstract][Full Text] [Related]
3. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials.
Szegedi A; Zhao J; van Willigenburg A; Nations KR; Mackle M; Panagides J
BMC Psychiatry; 2011 Jun; 11():101. PubMed ID: 21689438
[TBL] [Abstract][Full Text] [Related]
4. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
J Affect Disord; 2010 Apr; 122(1-2):27-38. PubMed ID: 20096936
[TBL] [Abstract][Full Text] [Related]
5. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
Bipolar Disord; 2009 Nov; 11(7):673-86. PubMed ID: 19839993
[TBL] [Abstract][Full Text] [Related]
6. Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder.
Landbloom RL; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
J Affect Disord; 2016 Jan; 190():103-110. PubMed ID: 26496015
[TBL] [Abstract][Full Text] [Related]
7. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses.
Azorin JM; Sapin C; Weiller E
J Affect Disord; 2013 Feb; 145(1):62-9. PubMed ID: 22868059
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
[TBL] [Abstract][Full Text] [Related]
9. Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes.
Houston JP; Ketter TA; Case M; Bowden C; Degenhardt EK; Jamal HH; Tohen M
J Psychiatr Res; 2011 Feb; 45(2):169-73. PubMed ID: 20541220
[TBL] [Abstract][Full Text] [Related]
10. Asenapine versus olanzapine in acute mania: a double-blind extension study.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
Bipolar Disord; 2009 Dec; 11(8):815-26. PubMed ID: 19832806
[TBL] [Abstract][Full Text] [Related]
11. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
Leucht S; Zhao J
J Psychopharmacol; 2014 Apr; 28(4):387-94. PubMed ID: 24429222
[TBL] [Abstract][Full Text] [Related]
12. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data.
Suppes T; Brown E; Schuh LM; Baker RW; Tohen M
J Affect Disord; 2005 Dec; 89(1-3):69-77. PubMed ID: 16253344
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone.
Kemp DE; Johnson E; Wang WV; Tohen M; Calabrese JR
J Clin Psychiatry; 2011 Sep; 72(9):1236-41. PubMed ID: 21457677
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of treatment effects with aripiprazole versus placebo in a study of manic or mixed episodes associated with pediatric bipolar I disorder.
Youngstrom E; Zhao J; Mankoski R; Forbes RA; Marcus RM; Carson W; McQuade R; Findling RL
J Child Adolesc Psychopharmacol; 2013 Mar; 23(2):72-9. PubMed ID: 23480324
[TBL] [Abstract][Full Text] [Related]
15. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.
McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
J Affect Disord; 2010 Nov; 126(3):358-65. PubMed ID: 20537396
[TBL] [Abstract][Full Text] [Related]
16. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.
McIntyre RS; Tohen M; Berk M; Zhao J; Weiller E
J Affect Disord; 2013 Sep; 150(2):378-83. PubMed ID: 23712026
[TBL] [Abstract][Full Text] [Related]
17. Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania.
Berk M; Ng F; Wang WV; Tohen M; Lubman DI; Vieta E; Dodd S
J Affect Disord; 2008 Sep; 110(1-2):126-34. PubMed ID: 18280579
[TBL] [Abstract][Full Text] [Related]
18. Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine: Results From a 3-Week, Randomized, Placebo-Controlled Trial.
Xiao L; Ganocy SJ; Findling RL; Chang K; DelBello MP; Kane JM; Tohen M; Xiang YT; Correll CU
J Clin Psychiatry; 2017; 78(9):e1158-e1166. PubMed ID: 28922591
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.
Niufan G; Tohen M; Qiuqing A; Fude Y; Pope E; McElroy H; Ming L; Gaohua W; Xinbao Z; Huichun L; Liang S
J Affect Disord; 2008 Jan; 105(1-3):101-8. PubMed ID: 17531327
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis.
Potkin SG; Phiri P; Szegedi A; Zhao J; Alphs L; Cazorla P
Schizophr Res; 2013 Nov; 150(2-3):442-9. PubMed ID: 24075603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
